A study of Pacitol Inj. for dialysis patients with parathyroid issues
Part of Hormones & metabolism clinical trials.
This study watches how well the drug Pacitol Inj. works and how safe it is in people on dialysis who have overactive parathyroid glands caused by kidney disease. It follows patients who are already prescribed this drug by their doctor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are on hemodialysis for chronic kidney disease
- You have secondary hyperparathyroidism (overactive parathyroid glands due to kidney failure)
- Your doctor has decided to treat you with Pacitol Inj. as part of your regular care
- You do not have high blood calcium levels or vitamin D toxicity
- You are not pregnant or breastfeeding
- You have not taken part in another drug trial in the past 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies etelcalcetide in children who have chronic kidney disease and too much parathyroid hormone while on hemodialysis. It aims to safely lower the hormone levels and help manage related bone/mineral problems.
This study tests a new extended-release capsule (CTAP101) for children aged 8 to under 18 with moderate to severe chronic kidney disease (CKD). The goal is to see how the drug works in the body, if it's safe, and if it can help control mineral and hormone levels that are often out of balance in CKD.
This Phase 3 trial tests etelcalcetide to lower a hormone called parathyroid hormone (PTH) in children who have kidney disease and secondary hyperparathyroidism while on hemodialysis. It may help control bone/mineral problems, but the study also checks heart rhythm safety and medication stability.
This study wants to see if measuring parathyroid hormone (PTH) levels during surgery helps guide how much parathyroid tissue to remove. It is for people who need surgery for hyperparathyroidism caused by kidney disease.
This trial tests a new medicine called MT1013 for people with secondary hyperparathyroidism who are on dialysis. It may help control high parathyroid hormone levels when current treatments are not enough.
This study tests a new injectable medicine called MT1013 for people with secondary hyperparathyroidism who are on regular kidney dialysis. It aims to see if MT1013 can help control high parathyroid hormone levels safely.
Hear when a new Chronic Kidney Disease 5D trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.